| [1] |
Hadji P, Ziller V, Kyvernitakis J,et al. Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis[J]. Breast Cancer Res Treat,2013,138(1):185-191.
|
| [2] |
Nekhlyudov L, Li L, Ross-Degnan D, et al. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer[J].Breast Cancer Res Treat,2011,130(2):681-689.
|
| [3] |
Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer[J].Breast Cancer Res Treat,2011,126(2):529-537.
|
| [4] |
Makubate B, Donnan PT, Dewar JA,et al. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality[J].Br J Cancer,2013,108(7):1515-1524.
|
| [5] |
McCowan C, Shearer J, Donnan PT, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer [J].Br J Cancer,2008,99(11):1763-1768.
|
| [6] |
Lin JH, Zhang SM, Manson JE,et al. Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention[J]. Cancer Prev Res (Phila),2011,4(9):1360-1365.
|
| [7] |
Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy[J]. Crit Rev Oncol Hematol,2010,73 (2):156-166.
|
| [8] |
Oberguggenberger AS, Sztankay M, Beer B, et al. Adherence evaluation of endocrine treatment in breast cancer:methodological aspects[J].BMC Cancer,2012,12:474.
|
| [9] |
Font R, Espinas JA, Gil-Gil M,et al. Prescription refill,patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain[J].Br J Cancer,2012,107(8):1249-1256.
|
| [10] |
Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses[J].Cancer,2003,98(9):1802-1810.
|
| [11] |
Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98[J]. J Clin Oncol, 2007,25(5):486-492.
|
| [12] |
Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer[J].N Engl J Med,2004,350(11):1081-1092.
|
| [13] |
Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer[J]. N Engl J Med,2003,349(19):1793-1802.
|
| [14] |
Fisher B,Dignam J,Bryant J,et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors[J].J Natl Cancer Inst,1996,88(21):1529-1542.
|
| [15] |
Friese CR,Pini TM, Li Y,et al. Adjuvant Endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer[J]. Breast Cancer Res Treat,2013,138(3):931-939.
|
| [16] |
Bell RJ, Fradkin P, Schwarz M, et al. Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis[J].Menopause,2013,20(1):15-21.
|
| [17] |
Partridge AH, LaFountain A, Mayer E,et al. Adherence to initial adjuvant anastrozole therapy among women with earlystage breast cancer[J].J Clin Oncol,2008,26(4):556-562.
|
| [18] |
Neugut AI, Subar M, Wilde ET, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer[J].J Clin Oncol,2011,29(18):2534-2542.
|
| [19] |
Hershman DL, Kushi LH, Shao T, et al.Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients[J]. J Clin Oncol,2010,28(27):4120-4128.
|
| [20] |
Barron TI, Connolly R, Bennett K,et al. Early discontinuation of tamoxifen: a lesson for oncologists[J]. Cancer,2007,109(5):832-839.
|
| [21] |
Cluze C, Rey D, Huiart L,et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer:determinants of interruptions vary over time[J]. Ann Oncol,2012,23(4):882-890.
|
| [22] |
Kahn KL, Schneider EC, Malin JL,et al. Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use[J].Med Care,2007,45(5):431-439.
|
| [23] |
Kimmick G,Anderson R,Camacho F,et al.Adjuvant hormonal therapy use among insured, low-income women with breast cancer[J].J Clin Oncol,2009,27(21):3445-3451.
|
| [24] |
Owusu C, Buist DS, Field TS, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptorpositive breast cancer[J]. J Clin Oncol, 2008,26 (4):549-555.
|
| [25] |
Wigertz A, Ahlgren J, Holmqvist M, et al. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study[J]. Breast Cancer Res Treat,2012,133(1):367-373.
|
| [26] |
Huiart L, Dell’Aniello S, Suissa S. Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer[J]. Br J Cancer, 2011,104(10):1558-1563.
|
| [27] |
Sedjo RL, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer[J]. Breast Cancer Res Treat,2011,125(1):191-200.
|
| [28] |
Partridge AH,Wang PS,Winer EP,et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer[J].J Clin Oncol,2003,21(4):602-606.
|
| [29] |
Lash TL, Fox MP, Westrup JL,et al. Adherence to tamoxifen over the five-year course[J]. Breast Cancer Res Treat,2006,99(2):215-220.
|
| [30] |
Osterberg L,Blaschke T.Adherence to medication[J].N Engl J Med,2005,353(5):487-497.
|
| [31] |
Davidson B, Vogel V, Wickerham L. Oncologist-patient discussion of adjuvant hormonal therapy in breast cancer:results of a linguistic study focusing on adherence and persistence to therapy[J].J Support Oncol,2007,5(3):139-143.
|
| [32] |
Fontein DB, Nortier JW, Liefers GJ, et al. High noncompliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial[J]. Eur J Surg Oncol,2012,38(2):110-117.
|
| [33] |
Dittmer C, Roeder K, Hoellen F,et al.Compliance to adjuvant therapy in breast cancer patients[J]. Eur J Gynaecol Oncol,2011,32(3):280-282.
|
| [34] |
Cella D, Fallowfield LJ. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy[J].Breast Cancer Res Treat,2008,107(2):167-180.
|
| [35] |
McCowan C,Thompson AM.The importance of nonpharmacogenetic factors in endocrine therapy[J]. Pharmacogenomics,2012,13(6):721-728.
|
| [36] |
Güth U,Myrick ME,Kilic N,et al.Compliance and persistence of endocrine adjuvant breast cancer therapy[J]. Breast Cancer Res Treat,2012,131(2):491-499.
|
| [37] |
Miaskowski C, Shockney L, Chlebowski RT. Adherence to endocrine therapy for breast cancer[J]. Clin J Oncol Nurs,2008,12(2):213-221.
|
| [38] |
Güth U, Huang DJ, Schötzau A, et al. Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer[J]. Br J Cancer,2008,99(3):428-433.
|
| [39] |
Yu KD, Zhou Y, Liu GY,et al. A prospective, multicenter,controlled, observational study to evaluate the efficacy of a patient support program in improving patients’ persistence to adjuvant aromatase inhibitor medication for postmenopausal,early stage breast cancer[J]. Breast Cancer Res Treat, 2012,134(1):307-313.
|
| [40] |
Markkula A, Hietala M, Henningson M,et al. Clinical profiles predict early nonadherence to adjuvant endocrine treatment in a prospective breast cancer cohort[J].Cancer Prev Res(Phila),2012,5(5):735-745.
|
| [41] |
Schmid SM, Eichholzer M, Bovey F,et al.Impact of body mass index on compliance and persistence to adjuvant breast cancer therapy[J]. Breast,2012,21(4):487-492.
|
| [42] |
Hadji P, Blettner M, Harbeck N, et al. The Patient’ s Anastrozole Compliance to Therapy ( PACT) Program: a randomized,in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer[J]. Ann Oncol,2013,24(6):1505-1512.
|
| [43] |
Neven P, Markopoulos C, Tanner M,et al. The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the Compliance of ARomatase Inhibitors AssessmenT In Daily practice through Educational approach (CARIATIDE) study[J].Breast,2014,23(4):393-399.
|
| [44] |
Ell K, Vourlekis B, Xie B,et al. Cancer treatment adherence among low-income women with breast or gynecologic cancer:a randomized controlled trial of patient navigation[J]. Cancer,2009,115(19):4606-4615.
|
| [45] |
宋淑芬,佘晓佳,秦期,等.应用个案管理模式提高乳腺癌患者内分泌治疗的依从性[J]. 护理学报,2011,18(18):24-26.
|
| [46] |
胡夕春,Angelo Di Leo,王晓稼,等. Luminal 型晚期乳腺癌的共识和争议[J/CD]. 中华乳腺病杂志:电子版,2013,7(2):76-79.
|